Cochrane · systematic review · CD009612
Nasal decongestants in monotherapy for the common cold
Deckx, L, De Sutter, AIM, Guo, L, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Acute Respiratory InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 6.3%Ungraded 9 · 56.3%Very low 0 · 0%Low 5 · 31.3%Moderate 1 · 6.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings for single‐dose nasal decongestant compared to placebo in adults with the common cold
Population: adult patients with the common cold
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: subjective symptom score ‐ 3 hours after dosing Summary of findings for single‐dose nasal decongestant vs placebo | no estimate extracted | 4 studies · 540 participants | Ungraded |
Primary outcome: overall patient well‐being ‐ 3 hours after dosing Summary of findings for single‐dose nasal decongestant vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: all adverse events Summary of findings for single‐dose nasal decongestant vs placebo | no estimate extracted | 2 studies · 82 participants | Ungraded |
Summary of findings for multi‐dose nasal decongestant compared to placebo in adults with the common cold
Population: adult patients with the common cold
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing Summary of findings for multi‐dose nasal decongestant vs placebo | no estimate extracted | 2 studies · 94 participants | Low Downgraded: risk of bias |
Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosingOral Summary of findings for multi‐dose nasal decongestant vs placebo | no estimate extracted | 1 study · 33 participants | Ungraded |
Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosingTopical Summary of findings for multi‐dose nasal decongestant vs placebo | no estimate extracted | 1 study · 61 participants | Ungraded |
Primary outcome: overall patient well‐being Summary of findings for multi‐dose nasal decongestant vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: all adverse events Summary of findings for multi‐dose nasal decongestant vs placebo | OR 0.98 [0.68, 1.4] | 7 studies · 1195 participants | Low Downgraded: risk of bias, imprecision |
Secondary outcome: all adverse eventsOral Summary of findings for multi‐dose nasal decongestant vs placebo | OR 0.95 [0.65, 1.39] | 6 studies · 1134 participants | Low Downgraded: risk of bias, imprecision |
Secondary outcome: all adverse eventsTopical Summary of findings for multi‐dose nasal decongestant vs placebo | no estimate extracted | 1 study · 61 participants | Ungraded |
Summary of findings for all doses of nasal decongestant compared to placebo in adults with the common cold
Population: adult patients with the common cold
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing Summary of findings for all doses of nasal decongestant vs placebo | no estimate extracted | 3 studies · 146 participants | Moderate Downgraded: risk of bias, imprecision |
Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosingOral Summary of findings for all doses of nasal decongestant vs placebo | no estimate extracted | 2 studies · 85 participants | Low Downgraded: risk of bias, imprecision |
Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing Topical Summary of findings for all doses of nasal decongestant vs placebo | no estimate extracted | 1 study · 61 participants | Ungraded |
Primary outcome: subjective symptom score (AUC) ‐ 3 hours after dosingOral Summary of findings for all doses of nasal decongestant vs placebo | no estimate extracted | 2 studies · 260 participants | Low Downgraded: risk of bias, imprecision |
Primary outcome: overall patient well‐being Summary of findings for all doses of nasal decongestant vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Secondary outcome: All adverse events Summary of findings for all doses of nasal decongestant vs placebo | no estimate extracted | NR | No studies |